Christopher R. Cline, Chief Financial Officer at Travere Therapeutics, sold TVTX on Sep 2, 2026
Data as of Oct 16
▼ SELL$42.6K642 shares at $66.37Christopher R. Cline Chief Financial OfficerTVTX Travere Therapeutics, Inc.
- Traded
- Sep 2, 2026
- Disclosed
- Sep 3, 2026
- Filed
- 1 day after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
TVTX since disclosure
−25.5%
after the sale
Similar stocks (XLV) since disclosure
+2.0%
XLV — its sector index fund
Change in closing price from Sep 3, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.